サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654642

エレクトロポレーション機器の世界市場：2025年～2033年

Global Electroporation Instruments Market - 2025-2033

出版日
ページ情報
英文 159 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
エレクトロポレーション機器の世界市場：2025年～2033年
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 159 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

エレクトロポレーション機器の世界市場は、2024年に2億5,142万米ドルに達し、2033年までには3億7,404万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは4.5%で成長します。

エレクトロポレーション機器は、エレクトロポレーションを促進するために使用される装置です。エレクトロポレーションとは、細胞に短い電気パルスを印加して、細胞膜の透過性を一時的に高める技術です。これは、DNA、RNA、タンパク質、薬剤などの物質を細胞内に導入することを可能にするものであり、バイオテクノロジー、遺伝子工学、医療におけるさまざまな応用に不可欠なプロセスです。エレクトロポレーションは、従来の方法と比較して、より効率的かつ直接的に分子物質を細胞内に導入できるため、遺伝子研究、ドラッグデリバリー、ワクチン接種、タンパク質生産などに広く利用されています。真核細胞、原核細胞を含む様々な種類の細胞を扱うことができ、その精密さ、有効性、能力は高く評価されています。

エレクトロポレーション機器市場は、バイオテクノロジーの進歩、研究活動の活発化、遺伝子編集や治療用途への需要の高まりなどを背景に、大きな成長を遂げています。例えば、2024年6月、Porton Advancedは細胞治療プラットフォームにMaxCyte cGMPグレードのExPERT GTxフローエレクトロポレーション装置を導入し、同社はこの臨床グレードのフローエレクトロポレーションシステムを保有する中国初の細胞治療CDMOとなりました。

市場力学：

促進要因と抑制要因

技術進歩の高まり

技術進歩の高まりがエレクトロポレーション機器市場の成長を大きく後押ししており、予測期間中も市場を牽引するとみられます。エレクトロポレーションは、特に電気化学療法によるがん治療において極めて重要な技術となっています。この方法では、腫瘍に電気パルスを印加することで細胞膜の透過性を高め、化学療法剤がより効果的にがん細胞に入り込むようにします。技術の進歩により、この手法の精度と安全性が向上し、皮膚や皮下の腫瘍患者の治療成績が向上しています。

例えば、2024年10月、AngioDynamicsはユニバーシティ・カレッジ・ロンドン病院（UCLH）と共同で、単巣性の中リスク前立腺がんの治療に対するナノナイフシステムの長期的効果を評価する前向き登録研究を開始しました。このナノナイフシステムは、不可逆的なエレクトロポレーション技術を使用しており、高電圧の電気パルスを照射することで細胞膜に小さな孔を開け、周囲の組織に害を与えることなく制御された細胞死をもたらすことで腫瘍を治療します。

CRISPR-Cas9のような遺伝子編集技術の開発により、エレクトロポレーション機器の需要が高まっています。エレクトロポレーションは、遺伝子編集成分の細胞内への効率的な送達を容易にし、それによって研究や治療応用を進展させます。このため、遺伝子工学や治療介入におけるエレクトロポレーション機器の採用が急増しています。

エレクトロポレーション機器の高コスト

エレクトロポレーション機器のコストが高いため、特に予算に制約のある小規模の研究所や研究機関では、アクセスや導入が制限され、市場の成長が著しく阻害されます。例えば、新しいエレクトロポレーション・システムのコストは、モデル、機能、性能にもよりますが、通常3,000ドルから20,000ドルです。

エレクトロポレーション機器に多額の費用がかかるため、その入手は資金力のある研究所や研究センターに限られ、小規模の研究機関はそのような技術に投資することができません。このような格差は、先端研究ツールへのアクセスの不平等を招き、市場全体の成長を阻害します。研究機関がこれらの機器を調達・維持するために必要なリソースを欠いている可能性があるため、高額な機器コストは研究プロジェクトや新しい治療法の開発の遅れにつながる可能性があります。このような研究活動の停滞は、この分野における科学の進歩や技術革新を妨げる可能性があります。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • スニペット：製品タイプ別
  • スニペット：用途別
  • スニペット：エンドユーザー別
  • スニペット：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 技術の進歩の高まり
    • 抑制要因
      • エレクトロポレーション機器のコストが高い
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名なプレーヤー
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 エレクトロポレーション機器市場、製品タイプ別

  • 機器
    • トータルエレクトロポレーションシステム
    • 真核生物電気穿孔システム
    • 微生物電気穿孔システム
  • アクセサリー
    • エレクトロポレーションキュベット
    • 電極
    • チェンバース
    • キット
    • その他

第6章 エレクトロポレーション機器市場、用途別

  • タンパク質生産
  • ドラッグデリバリー
  • 生物調査

第7章 エレクトロポレーション機器市場、エンドユーザー別

  • 病院
  • 研究所
  • バイオテクノロジー・製薬企業
  • 研究・学術機関
  • その他

第8章 エレクトロポレーション機器市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Bio-Rad Laboratories, Inc.
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • MaxCyte
  • Lonza Group
  • BEX CO., LTD.
  • Celetrix, LLC.
  • Harvard Bioscience, Inc.
  • Bulldog Bio, Inc.
  • Spectrocell Inc.

第11章 前提条件と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第12章 付録

目次
Product Code: MD3818

The global electroporation instruments market reached US$ 251.42 million in 2024 and is expected to reach US$ 374.04 million by 2033, growing at a CAGR of 4.5% during the forecast period 2025-2033.

Electroporation instruments are devices used to facilitate electroporation, a technique that involves applying short electrical pulses to cells to temporarily increase the permeability of their membranes. This allows for the introduction of substances like DNA, RNA, proteins, or drugs into the cell, a process that is essential for various applications in biotechnology, genetic engineering, and medicine. Electroporation is widely used in genetic research, drug delivery, vaccination, and protein production, as it allows for more efficient and direct transfer of molecular substances into cells compared to traditional methods. The instruments are highly valued for their precision, effectiveness, and ability to handle a variety of cell types, including both eukaryotic and prokaryotic cells.

The electroporation instruments market is experiencing significant growth, driven by advancements in biotechnology, increased research activities, and the rising demand for gene editing and therapeutic applications. For instance, in June 2024, Porton Advanced introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system.

Market Dynamics: Drivers & Restraints

Rising technological advancements

The rising technological advancements are significantly driving the growth of the electroporation instruments market and are expected to drive the market over the forecast period. Electroporation has become a pivotal technique in cancer treatment, particularly through electrochemotherapy. This method involves applying electrical pulses to tumors, increasing cell membrane permeability and allowing chemotherapeutic agents to enter cancer cells more effectively. Technological advancements have improved the precision and safety of this technique, leading to better treatment outcomes for patients with cutaneous and subcutaneous tumors.

For instance, in October 2024, AngioDynamics with the University College London Hospital (UCLH) launched a prospective registry study evaluating the long-term effects of the NanoKnife system for treating unifocal intermediate-risk prostate cancer. This NanoKnife system uses irreversible electroporation technology to treat tumors by delivering high-voltage electrical pulses that create tiny pores in cell membranes, leading to controlled cell death without harming surrounding tissues.

The development of gene editing technologies, such as CRISPR-Cas9, has increased the demand for electroporation instruments. Electroporation facilitates the efficient delivery of gene-editing components into cells, thereby advancing research and therapeutic applications. This has led to a surge in the adoption of electroporation instruments in genetic engineering and therapeutic interventions.

The high cost of the electroporation instruments

The high cost of electroporation instruments significantly hampers the growth of the market by limiting accessibility and adoption, particularly among smaller laboratories and research institutions with constrained budgets. For instance, the cost of the new electroporation systems typically ranges from $3,000 to $20,000, depending on the model, features and capabilities.

The substantial expense of electroporation instruments restricts their acquisition to well-funded laboratories and research centers, leaving smaller institutions unable to invest in such technologies. This disparity results in unequal access to advanced research tools, hindering the overall growth of the market. High equipment costs can lead to delays in research projects and the development of new therapies, as institutions may lack the necessary resources to procure and maintain these instruments. This slowdown in research activities can impede scientific progress and innovation within the field.

Segment Analysis

The global electroporation instruments market is segmented based on product type, application, end-user and region.

Product Type:

The instruments segment is expected to dominate the electroporation instruments market share

In the electroporation instruments market, the instruments segment including total electroporation systems, eukaryotic electroporation systems and microbial electroporation systems holds a dominant position over the accessories segment. This dominance is primarily due to the essential role that electroporation systems play in the process, as they generate the electrical pulses necessary for cell membrane permeabilization.

These electroporation instruments are the core devices for researchers to transfect even the most difficult cell types with excellent efficiency, cell recovery, and repeatability and these instruments apply electrical pulses to cells, facilitating the introduction of substances like DNA, RNA, or drugs. The market for these systems is substantial, with projections indicating significant growth.

For instance, in April 2023, Thermo Fisher Scientific launched the Invitrogen Neon NxT Electroporation System, which allows researchers to transfect even the most difficult cell types with excellent efficiency, cell recovery, and repeatability. Neon NxT electrodes are ideally positioned and have a small surface area to provide a more uniform electric field and keep physiological parameters stable during transfection. These advantages allow the intended alteration to occur in more cells, with fewer cells lost during the transfection process. The new system also has an enhanced feedback loop and ergonomic advancements for ease of usage.

Geographical Analysis

North America is expected to hold a significant position in the electroporation instruments market share

North America especially the United States boosts a well-established healthcare system with state-of-the-art research laboratories, facilitating the adoption and integration of advanced technologies like electroporation instruments. The presence of major market players in the region particularly in the United States fosters innovations and advancements in electroporation instruments.

For instance, in March 2022, Thermo Fisher Scientific introduced a new large-volume electroporation system that allows cell therapy developers to more easily move from clinical development to commercial manufacturing. The Gibco CTS Xenon Electroporation System leverages a closed, highly flexible design to facilitate gene modifications without the use of traditional viral vectors. The electroporation approach enables the introduction of a payload into a cell by temporarily increasing cell permeability using an electrical pulse.

Asia-Pacific is growing at the fastest pace in the electroporation instruments market

The region is witnessing significant progress in biotechnology and molecular biology research. Electroporation instruments are essential for gene editing, protein production, and other biomedical applications. The expansion of research facilities and increased funding are contributing to the adoption of these technologies.

For instance, China has been leading investments in biotechnology with initiatives such as "Made in China 2025," which focuses on integrating advanced technologies into manufacturing and healthcare sectors. This initiative is expected to bolster the demand for electroporation instruments as part of broader biotechnological advancements.

As emerging economies in Asia-Pacific continue to develop their biotech sectors, there is an increasing demand for electroporation instruments for applications in biomedical research and therapeutic delivery56. Countries like India are investing heavily in science and technology, which further supports market growth

Competitive Landscape

The major global players in the electroporation instruments market include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, MaxCyte, Lonza Group, BEX CO., LTD., Celetrix, LLC., Harvard Bioscience, Inc., Bulldog Bio, Inc., Spectrocell Inc. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global electroporation instruments market report delivers a detailed analysis with 62 key tables, more than 53 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Electroporation Instruments
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Electroporation Instruments Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Instruments*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Total Electroporation Systems
    • 5.2.4. Eukaryotic Electroporation Systems
    • 5.2.5. Microbial Electroporation Systems
  • 5.3. Accessories
    • 5.3.1. Electroporation Cuvettes
    • 5.3.2. Electrodes
    • 5.3.3. Chambers
    • 5.3.4. Kits
    • 5.3.5. Others

6. Electroporation Instruments Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Protein Production*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Drug Delivery
  • 6.4. Biomedical Research

7. Electroporation Instruments Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Laboratories
  • 7.4. Biotechnology and Pharmaceutical Companies
  • 7.5. Research and Academic Institutions
  • 7.6. Others

8. Electroporation Instruments Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Bio-Rad Laboratories, Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Thermo Fisher Scientific Inc.
  • 10.3. Merck KGaA
  • 10.4. MaxCyte
  • 10.5. Lonza Group
  • 10.6. BEX CO., LTD.
  • 10.7. Celetrix, LLC.
  • 10.8. Harvard Bioscience, Inc.
  • 10.9. Bulldog Bio, Inc.
  • 10.10. Spectrocell Inc.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us